Truist lowered the firm’s price target on Procept BioRobotics to $37 from $49 and keeps a Buy rating on the shares as part of a broader research note on MedTech. The sector continues to trade down on fear of exposure to GLP-1s, and even good Q3 earnings may not matter amid a GLP-1 sector overhang, the analyst tells investors in a research note. While Truist continues to believe that the dramatic GLP1-driven sector pullback is likely overdone and that “narrative” is driving indiscriminate selling more so than a tangible fundamental impact, it’s hard to say when/if the GLP-1 overhang will subside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRCT:
- Procept says NICE gave ‘standard arrangements’ recommendation on Aquablation
- Procept BioRobotics announces new corporate headquarters in San Jose
- Procept BioRobotics receives FDA IDE to investigate Aquablation
- Procept announces first commercial Aquablation therapy procedures in Japan
- PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston